Tempus AI/$TEM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
- Ticker
- $TEM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,800
- Headquarters
- Chicago, United States
- Website
- www.tempus.com
Tempus AI Metrics
BasicAdvanced
$12B
-
-$1.43
3.54
-
Price and volume
Market cap
$12B
Beta
3.54
52-week high
$96.29
52-week low
$40.77
Average daily volume
7.1M
Financial strength
Current ratio
3.297
Quick ratio
3.013
Long term debt to equity
3.218
Total debt to equity
3.246
Interest coverage (TTM)
-5.10%
Profitability
EBITDA (TTM)
-202.433
Gross margin (TTM)
63.98%
Net profit margin (TTM)
-17.77%
Operating margin (TTM)
-19.69%
Effective tax rate (TTM)
2.10%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-8.83%
Return on equity (TTM)
-67.44%
Valuation
Price to revenue (TTM)
8.044
Price to book
26.19
Price to tangible book (TTM)
-32.6
Price to free cash flow (TTM)
-42.199
Free cash flow yield (TTM)
-2.37%
Free cash flow per share (TTM)
-1.534
Growth
Revenue change (TTM)
50.43%
Earnings per share change (TTM)
22.29%
What the Analysts think about Tempus AI
Analyst ratings (Buy, Hold, Sell) for Tempus AI stock.
Analyst projections of the future price of Tempus AI stock.
Bulls say / Bears say
Tempus’s Q2 revenue rose 22% to $382.5 million, with oncology testing volumes up 31% and its Insights data business up 36%. It raised its 2026 revenue outlook to about $1.6 billion, implying roughly 25% growth. (Tempus)
Pharma data licensing is showing commercial traction: Tempus reported about $200 million in new Data and Applications licences in Q2, and extended its Recursion data partnership through 2029 with committed payments under the revised agreement. More long-term deals could make this business a larger growth engine. (Tempus, Nasdaq)
Tempus has potential to grow revenue per test as well as test volumes: the FDA approved its tumour-only xT test, which the company says can move tissue testing to ADLT pricing, while MRD testing volume rose to 9,000 in Q2 from 6,500 in the prior quarter. (Tempus)
Tempus used $80.8 million of operating cash in the first half of 2026, so the business had not yet demonstrated that growth was self-funding. Continued cash burn could limit strategic flexibility if profitability takes longer than expected. (Last10K)
The Q2 GAAP profit offers limited proof of durable operating profitability: the $5.6 million net income included $98.5 million of unrealised gains on marketable securities. If those gains do not recur, reported earnings may remain weak while operating costs are high. (Tempus)
Several large pharmaceutical data contracts are approaching renewal windows, creating a risk that strong recent licensing growth may not persist if customers do not renew on similar terms. Goldman Sachs has highlighted these renewals as a key test for the data business. (GMT8Press)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
Tempus AI Financial Performance
Revenues and expenses
Tempus AI Earnings Performance
Company profitability
Upcoming events
No upcoming events
Tempus AI News
AllArticlesVideos
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
MarketBeat7 hours ago
Tempus to Report Third Quarter 2026 Financial Results on November 2
Business Wire4 days ago
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Business Wire6 days ago
Funds containing Tempus AI
AllUSDGBPEUR
Fund name | Fund size | $TEM weighting |
|---|---|---|
L&G Artificial Intelligence£AIAG | $2.1B | 2.32% |
L&G Artificial Intelligence$AIAI | $2.1B | 2.32% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.83% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.83% |
iShares Healthcare Innovation£DRDR | £1B | 0.78% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.